HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis
NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock
Overall HRMY gets a fundamental rating of 7 out of 10. We evaluated HRMY against 195 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. HRMY is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes HRMY very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
In multiple years HRMY reported negative net income over the last 5 years.
In multiple years HRMY reported negative operating cash flow during the last 5 years.
1.2 Ratios
HRMY's Return On Assets of 13.21% is amongst the best of the industry. HRMY outperforms 96.24% of its industry peers.
With an excellent Return On Equity value of 20.55%, HRMY belongs to the best of the industry, outperforming 93.01% of the companies in the same industry.
With an excellent Return On Invested Capital value of 18.64%, HRMY belongs to the best of the industry, outperforming 94.09% of the companies in the same industry.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.06%. This is significantly below the industry average of 43.99%.
The last Return On Invested Capital (18.64%) for HRMY is above the 3 year average (18.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| ROIC | 18.64% |
ROA(3y)16.93%
ROA(5y)-27.92%
ROE(3y)30.4%
ROE(5y)N/A
ROIC(3y)18.06%
ROIC(5y)N/A
1.3 Margins
HRMY has a better Profit Margin (17.98%) than 90.86% of its industry peers.
HRMY has a better Operating Margin (28.21%) than 92.47% of its industry peers.
In the last couple of years the Operating Margin of HRMY has grown nicely.
HRMY has a better Gross Margin (78.65%) than 83.33% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.21% | ||
| PM (TTM) | 17.98% | ||
| GM | 78.65% |
OM growth 3Y46.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HRMY is still creating some value.
Compared to 1 year ago, HRMY has less shares outstanding
Compared to 5 years ago, HRMY has less shares outstanding
The debt/assets ratio for HRMY has been reduced compared to a year ago.
2.2 Solvency
HRMY has an Altman-Z score of 5.99. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.99, HRMY belongs to the best of the industry, outperforming 82.26% of the companies in the same industry.
HRMY has a debt to FCF ratio of 0.83. This is a very positive value and a sign of high solvency as it would only need 0.83 years to pay back of all of its debts.
The Debt to FCF ratio of HRMY (0.83) is better than 96.24% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that HRMY is not too dependend on debt financing.
HRMY has a Debt to Equity ratio (0.28) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 0.83 | ||
| Altman-Z | 5.99 |
ROIC/WACC1.72
WACC10.82%
2.3 Liquidity
A Current Ratio of 3.24 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a Current ratio of 3.24. This is comparable to the rest of the industry: HRMY outperforms 51.08% of its industry peers.
HRMY has a Quick Ratio of 3.20. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a Quick ratio (3.20) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.2 |
3. Growth
3.1 Past
The earnings per share for HRMY have decreased strongly by -23.55% in the last year.
The Revenue has grown by 25.83% in the past year. This is a very strong growth!
Measured over the past years, HRMY shows a very strong growth in Revenue. The Revenue has been growing by 53.89% on average per year.
EPS 1Y (TTM)-23.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y53.89%
Revenue growth 5YN/A
Sales Q2Q%16.08%
3.2 Future
HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.92% yearly.
The Revenue is expected to grow by 24.18% on average over the next years. This is a very strong growth
EPS Next Y-2.88%
EPS Next 2Y15.95%
EPS Next 3Y25.88%
EPS Next 5Y37.92%
Revenue Next Year22.2%
Revenue Next 2Y20.59%
Revenue Next 3Y22.14%
Revenue Next 5Y24.18%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HRMY is valuated rather expensively with a Price/Earnings ratio of 19.18.
Based on the Price/Earnings ratio, HRMY is valued cheaper than 85.48% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.29, HRMY is valued a bit cheaper.
The Price/Forward Earnings ratio is 12.43, which indicates a correct valuation of HRMY.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 84.95% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HRMY to the average of the S&P500 Index (24.44), we can say HRMY is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.18 | ||
| Fwd PE | 12.43 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaper than 87.63% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HRMY is valued cheaply inside the industry as 91.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.48 | ||
| EV/EBITDA | 9.5 |
4.3 Compensation for Growth
HRMY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 25.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.95%
EPS Next 3Y25.88%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARMONY BIOSCIENCES HOLDINGS
NASDAQ:HRMY (1/21/2025, 4:53:55 PM)
Premarket: 42 +1.54 (+3.81%)40.46
+1.41 (+3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners72.67%
Inst Owner Change0.11%
Ins Owners0.51%
Ins Owner Change-52.83%
Market Cap2.31B
Analysts80
Price Target54.95 (35.81%)
Short Float %14.8%
Short Ratio7.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)213.04%
Min EPS beat(2)16.47%
Max EPS beat(2)409.61%
EPS beat(4)3
Avg EPS beat(4)106.73%
Min EPS beat(4)-7.85%
Max EPS beat(4)409.61%
EPS beat(8)6
Avg EPS beat(8)62.25%
EPS beat(12)9
Avg EPS beat(12)125.88%
EPS beat(16)12
Avg EPS beat(16)190.97%
Revenue beat(2)0
Avg Revenue beat(2)-1.35%
Min Revenue beat(2)-1.8%
Max Revenue beat(2)-0.91%
Revenue beat(4)0
Avg Revenue beat(4)-1.67%
Min Revenue beat(4)-2.34%
Max Revenue beat(4)-0.91%
Revenue beat(8)2
Avg Revenue beat(8)-1.13%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)0.22%
PT rev (1m)14.36%
PT rev (3m)24.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.4%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.18 | ||
| Fwd PE | 12.43 | ||
| P/S | 3.38 | ||
| P/FCF | 10.48 | ||
| P/OCF | 10.44 | ||
| P/B | 3.87 | ||
| P/tB | 4.83 | ||
| EV/EBITDA | 9.5 |
EPS(TTM)2.11
EY5.22%
EPS(NY)3.25
Fwd EY8.04%
FCF(TTM)3.86
FCFY9.54%
OCF(TTM)3.87
OCFY9.58%
SpS11.96
BVpS10.46
TBVpS8.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| ROCE | 25.09% | ||
| ROIC | 18.64% | ||
| ROICexc | 40.12% | ||
| ROICexgc | 60.28% | ||
| OM | 28.21% | ||
| PM (TTM) | 17.98% | ||
| GM | 78.65% | ||
| FCFM | 32.29% |
ROA(3y)16.93%
ROA(5y)-27.92%
ROE(3y)30.4%
ROE(5y)N/A
ROIC(3y)18.06%
ROIC(5y)N/A
ROICexc(3y)42.04%
ROICexc(5y)N/A
ROICexgc(3y)1605.28%
ROICexgc(5y)N/A
ROCE(3y)24.3%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y35.21%
ROICexc growth 5YN/A
OM growth 3Y46.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
F-Score6
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 0.83 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 3.11% | ||
| Cap/Sales | 0.11% | ||
| Interest Coverage | 10.98 | ||
| Cash Conversion | 102.01% | ||
| Profit Quality | 179.57% | ||
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.2 | ||
| Altman-Z | 5.99 |
F-Score6
WACC10.82%
ROIC/WACC1.72
Cap/Depr(3y)235.53%
Cap/Depr(5y)610.69%
Cap/Sales(3y)14.03%
Cap/Sales(5y)258.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
EPS Next Y-2.88%
EPS Next 2Y15.95%
EPS Next 3Y25.88%
EPS Next 5Y37.92%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y53.89%
Revenue growth 5YN/A
Sales Q2Q%16.08%
Revenue Next Year22.2%
Revenue Next 2Y20.59%
Revenue Next 3Y22.14%
Revenue Next 5Y24.18%
EBIT growth 1Y-3.52%
EBIT growth 3Y124.82%
EBIT growth 5YN/A
EBIT Next Year23.06%
EBIT Next 3Y30.27%
EBIT Next 5Y22.1%
FCF growth 1Y91.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.18%
OCF growth 3YN/A
OCF growth 5YN/A